FDA Oncology seeks consumer reps for the Oncologic Drugs Advisory Committee

Eric K. Singhi: FDA Oncology approves amivantamab and chemo for EGFR and NSCLC

FDA approved Neoadjuvant/Adjuvant Nivolumab for resectable NSCLC

Measuring Toxicity in Reproductive Organs during Oncology Drug Development – a FDA-ASCO Workshop

Dario Trapani: Very informative story on how clinical trials have been so far “tolerated” in their design

FDA seeks Consumer Representatives for the Oncologic Drugs Advisory Committee – FDA Oncology

Jennifer Marks: The new NSCLC FDA Oncology approvals

Taha Al-Juhaishi: Treatment of AML in the community setting

What oncologists say about the new approval of Lazertinib and amivantamab for advanced NSCLC

The OCE Summer Scholars Program wrapped up its 8th summer – FDA Oncology